EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of Prolyl Oligopeptidase Restores Prohibitin 2 Levels in Psychosis Models: Relationship to Cognitive Deficits in Schizophrenia

Èlia Vila iD, Raquel Pinacho iD, Roger Prades, Teresa Tarragó, Elena Castro, Eva Munarriz-Cuezva iD, J Javier Meana iD, Ania Eugui-Anta, Mònica Roldan iD, América Vera-Montecinos, Belén Ramos iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Èlia Vila und 10 weiteren Autor:innen. Beteiligte Einrichtung: Parc Sanitari Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Dr. Antoni Pujadas, 42, 08830 Sant Boi de Llobregat, Spain. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Psychotic Disorders, Schizophrenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Spanish Ministry of Education, culture and sports, CONICYT-Doctorado Becas Chile.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cognitive impairment represents one of the core features of schizophrenia. Prolyl Oligopeptidase (POP) inhibition is an emerging strategy for compensating cognitive deficits in hypoglutamatergic states such as schizophrenia, although little is known about how POP inhibitors exert their pharmacological activity. The mitochondrial and nuclear protein Prohibitin 2 (PHB2) could be dysregulated in schizophrenia. However, altered PHB2 levels in schizophrenia linked to N-methyl-D-aspartate receptor (NMDAR) activity and cognitive deficits are still unknown. To shed light on this, we measured the PHB2 levels by immunoblot in a postmortem dorsolateral prefrontal cortex (DLPFC) of schizophrenia subjects, in the frontal pole of mice treated with the NMDAR antagonists phencyclidine and dizocilpine, and in rat cortical astrocytes and neurons treated with dizocilpine. Mice and cells were treated in combination with the POP inhibitor IPR19. The PHB2 levels were also analyzed by immunocytochemistry in rat neurons. The PHB2 levels increased in DLPFC in cases of chronic schizophrenia and were associated with cognitive impairments. NMDAR antagonists increased PHB2 levels in the frontal pole of mice and in rat astrocytes and neurons. High levels of PHB2 were found in the nucleus and cytoplasm of neurons upon NMDAR inhibition. IPR19 restored PHB2 levels in the acute NMDAR inhibition. These results show that IPR19 restores the upregulation of PHB2 in an acute NMDAR hypoactivity stage suggesting that the modulation of PHB2 could compensate NMDAR-dependent cognitive impairments in schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionPsychotic DisordersSchizophreniaAnimalsRatsCognitionDizocilpine MaleateProhibitinsProlyl OligopeptidasesReceptors, N-Methyl-D-Aspartate

Stichwörter der Autor:innen

DLPFCPHB2cognitive deficitsdizocilpinepostmortemprolyl oligopeptidaseschizophrenia

Substanzen

Dizocilpine MaleateProhibitinsProlyl OligopeptidasesReceptors, N-Methyl-D-AspartatePhb2 protein, rat

Autor:innen und Institutionen

  • Parc Sanitari Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Dr. Antoni Pujadas, 42, 08830 Sant Boi de Llobregat, Spain.
  • Iproteos S.L., Baldiri i Reixac, 10, 08028 Barcelona, Spain.
  • Institute for Research in Biomedicine (IRB Barcelona), Baldiri i Reixac, 10, 08028 Barcelona, Spain.
  • Departamento de Fisiología y Farmacología, Universidad de Cantabria, Avda. Cardenal Herrera Oria s/n, 39011 Santander, Spain.
  • Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM (Biomedical Network Research Center of Mental Health), Institute of Health Carlos III, 28029 Madrid, Spain.
  • Department of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.

ORCID-Profile: Èlia Vila, Raquel Pinacho, Eva Munarriz-Cuezva, J Javier Meana, Mònica Roldan, Belén Ramos

Förderung

  • Instituto de Salud Carlos III
  • Spanish Ministry of Education, culture and sports
  • CONICYT-Doctorado Becas Chile
  • the Spanish Ministry of Education, Culture, and Sports

Zitieren

APA

Vila, È., Pinacho, R., Prades, R., Tarragó, T., Castro, E., Munarriz-Cuezva, E., Meana, J. J., Eugui-Anta, A., Roldan, M., Vera-Montecinos, A., & Ramos, B. (2023). Inhibition of Prolyl Oligopeptidase Restores Prohibitin 2 Levels in Psychosis Models: Relationship to Cognitive Deficits in Schizophrenia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076016

Vancouver

Vila È, Pinacho R, Prades R, Tarragó T, Castro E, Munarriz-Cuezva E, et al. Inhibition of Prolyl Oligopeptidase Restores Prohibitin 2 Levels in Psychosis Models: Relationship to Cognitive Deficits in Schizophrenia. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076016

BibTeX
@article{Vila2023,
  author = {Vila, Èlia and Pinacho, Raquel and Prades, Roger and Tarragó, Teresa and Castro, Elena and Munarriz-Cuezva, Eva and Meana, J Javier and Eugui-Anta, Ania and Roldan, Mònica and Vera-Montecinos, América and Ramos, Belén},
  title = {Inhibition of Prolyl Oligopeptidase Restores Prohibitin 2 Levels in Psychosis Models: Relationship to Cognitive Deficits in Schizophrenia},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076016}
}
Kostenlos starten →